What Can We Expect From BMY’s Q2 Earnings?

+20.56%
Upside
54.25
Market
65.41
Trefis
BMY: Bristol Myers Squibb logo
BMY
Bristol Myers Squibb

Bristol-Myers Squibb (NYSE: BMY) will report its Q2 earnings on July 28,2016. We expect blood thinning drug Eliquis, its Oncology division and Hepatitis C franchise could help boost its earnings. Here are the reasons why we think so.

 

BMY- PRE Earnings

Relevant Articles
  1. Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
  2. Is Bristol Myers Squibb Stock Undervalued At $50?
  3. Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
  4. Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
  5. Will Bristol Myers Squibb Stock Rise Post Q1?
  6. Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?

Source:

Sec Filings

Have more questions about Bristol-Myers Squibb? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Bristol-Myers Squibb

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology